Last 12 months
Inside the activity.
0 purchase rows · 93 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 6 |
| Dec 2025 | 0 | 16 |
| Jan 2026 | 0 | 2 |
| Feb 2026 | 0 | 49 |
| Mar 2026 | 0 | 5 |
| Apr 2026 | 0 | 1 |
| May 2026 | 0 | 6 |
| Jun 2026 | 0 | 5 |
| Jul 2026 | 0 | 3 |
| Aug 2026 | 0 | 0 |
| Sep 2026 | 0 | 0 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 15, 2020 Filed May 19, 2020 20:35 UTC |
Kewalramani ReshmaDirector · CEO & President
|
SaleCommon Stock | 2 | $274.37 | $548.74 |
DisclosureSEC source: 0001209191-20-030498 · doc4.xml · nonDerivative · entry 1 Kewalramani Reshma · CIK 0001735944 · Director · CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,723 F1 · kind: Transaction made pursuant to Dr. Kewalramani's company approved trading plan under Rule 10b5-1. F2 · price: Open market sales reported on this line occurred at a weighted average price of $274.37 (range $274.03 to $274.71). F3 · price: Dr. Kewalramani undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. Read SEC document |
| May 12, 2020 Filed May 14, 2020 20:17 UTC |
ALTSHULER DAVIDEVP, Global Research and CSO
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 1,304 | $0.00 Strike: $187.53 | $0.00 |
DisclosureSEC source: 0001209191-20-029183 · doc4.xml · derivative · entry 3 ALTSHULER DAVID · CIK 0001550395 · EVP, Global Research and CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,338 Underlying: Common Stock · 1,304 shares Expires 2029-02-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The option vests in 16 quarterly installments from 02/06/2019. Read SEC document |
| May 12, 2020 Filed May 14, 2020 20:17 UTC |
ALTSHULER DAVIDEVP, Global Research and CSO
|
SaleCommon Stock | 1,304 | $287.33 | $374,678.32 |
DisclosureSEC source: 0001209191-20-029183 · doc4.xml · nonDerivative · entry 2 ALTSHULER DAVID · CIK 0001550395 · EVP, Global Research and CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,902 F1 · kind: Transaction made pursuant to Dr. Altshuler's company approved trading plan under Rule 10b5-1. Read SEC document |
| May 12, 2020 Filed May 14, 2020 20:17 UTC |
ALTSHULER DAVIDEVP, Global Research and CSO
|
Exercise / conversionCommon Stock | 1,304 | $187.53 | $244,539.12 |
DisclosureSEC source: 0001209191-20-029183 · doc4.xml · nonDerivative · entry 1 ALTSHULER DAVID · CIK 0001550395 · EVP, Global Research and CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,206 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 12, 2020 Filed May 14, 2020 20:19 UTC |
LEIDEN JEFFREY MDirector · Executive Chairman
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 24,348 | $0.00 Strike: $155.57 | $0.00 |
DisclosureSEC source: 0001209191-20-029186 · doc4.xml · derivative · entry 21 LEIDEN JEFFREY M · CIK 0001242825 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 24,348 shares Expires 2028-02-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F14 · derivative.exercise_date: Fully vested. Read SEC document |
| May 12, 2020 Filed May 14, 2020 20:19 UTC |
LEIDEN JEFFREY MDirector · Executive Chairman
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 4,470 | $0.00 Strike: $91.05 | $0.00 |
DisclosureSEC source: 0001209191-20-029186 · doc4.xml · derivative · entry 20 LEIDEN JEFFREY M · CIK 0001242825 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 93,866 Underlying: Common Stock · 4,470 shares Expires 2026-02-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F14 · derivative.exercise_date: Fully vested. Read SEC document |
| May 12, 2020 Filed May 14, 2020 20:19 UTC |
LEIDEN JEFFREY MDirector · Executive Chairman
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 35,499 | $0.00 Strike: $96.87 | $0.00 |
DisclosureSEC source: 0001209191-20-029186 · doc4.xml · derivative · entry 19 LEIDEN JEFFREY M · CIK 0001242825 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 35,499 shares Expires 2024-07-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F14 · derivative.exercise_date: Fully vested. Read SEC document |
| May 12, 2020 Filed May 14, 2020 20:19 UTC |
LEIDEN JEFFREY MDirector · Executive Chairman
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 24,215 | $0.00 Strike: $187.53 | $0.00 |
DisclosureSEC source: 0001209191-20-029186 · doc4.xml · derivative · entry 18 LEIDEN JEFFREY M · CIK 0001242825 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 24,215 shares Expires 2029-02-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F14 · derivative.exercise_date: Fully vested. Read SEC document |
| May 12, 2020 Filed May 14, 2020 20:19 UTC |
LEIDEN JEFFREY MDirector · Executive Chairman
|
SaleCommon Stock | 100 | $288.42 | $28,842.00 |
DisclosureSEC source: 0001209191-20-029186 · doc4.xml · nonDerivative · entry 16 LEIDEN JEFFREY M · CIK 0001242825 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,983 F1 · kind: Transaction made pursuant to Dr. Leiden's company approved trading plan under Rule 10b5-1. Read SEC document |
| May 12, 2020 Filed May 14, 2020 20:19 UTC |
LEIDEN JEFFREY MDirector · Executive Chairman
|
SaleCommon Stock | 9,630 | $287.81 | $2,771,610.30 |
DisclosureSEC source: 0001209191-20-029186 · doc4.xml · nonDerivative · entry 15 LEIDEN JEFFREY M · CIK 0001242825 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,083 F1 · kind: Transaction made pursuant to Dr. Leiden's company approved trading plan under Rule 10b5-1. F3 · price: Dr. Leiden undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F13 · price: Open market sales reported on this line occurred at a weighted average price of $287.81 (range $287.37 to $288.27). Read SEC document |
| May 12, 2020 Filed May 14, 2020 20:19 UTC |
LEIDEN JEFFREY MDirector · Executive Chairman
|
SaleCommon Stock | 15,792 | $286.70 | $4,527,566.40 |
DisclosureSEC source: 0001209191-20-029186 · doc4.xml · nonDerivative · entry 14 LEIDEN JEFFREY M · CIK 0001242825 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,713 F1 · kind: Transaction made pursuant to Dr. Leiden's company approved trading plan under Rule 10b5-1. F3 · price: Dr. Leiden undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F12 · price: Open market sales reported on this line occurred at a weighted average price of $286.70 (range $286.37 to $287.31). Read SEC document |
| May 12, 2020 Filed May 14, 2020 20:19 UTC |
LEIDEN JEFFREY MDirector · Executive Chairman
|
SaleCommon Stock | 8,391 | $285.68 | $2,397,140.88 |
DisclosureSEC source: 0001209191-20-029186 · doc4.xml · nonDerivative · entry 13 LEIDEN JEFFREY M · CIK 0001242825 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,505 F1 · kind: Transaction made pursuant to Dr. Leiden's company approved trading plan under Rule 10b5-1. F3 · price: Dr. Leiden undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F11 · price: Open market sales reported on this line occurred at a weighted average price of $285.68 (range $285.36 to $286.35). Read SEC document |
| May 12, 2020 Filed May 14, 2020 20:19 UTC |
LEIDEN JEFFREY MDirector · Executive Chairman
|
SaleCommon Stock | 10,179 | $285.06 | $2,901,625.74 |
DisclosureSEC source: 0001209191-20-029186 · doc4.xml · nonDerivative · entry 12 LEIDEN JEFFREY M · CIK 0001242825 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 68,896 F1 · kind: Transaction made pursuant to Dr. Leiden's company approved trading plan under Rule 10b5-1. F3 · price: Dr. Leiden undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F10 · price: Open market sales reported on this line occurred at a weighted average price of $285.06 (range $284.36 to $285.35). Read SEC document |
| May 12, 2020 Filed May 14, 2020 20:19 UTC |
LEIDEN JEFFREY MDirector · Executive Chairman
|
SaleCommon Stock | 9,219 | $283.86 | $2,616,905.34 |
DisclosureSEC source: 0001209191-20-029186 · doc4.xml · nonDerivative · entry 11 LEIDEN JEFFREY M · CIK 0001242825 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 79,075 F1 · kind: Transaction made pursuant to Dr. Leiden's company approved trading plan under Rule 10b5-1. F3 · price: Dr. Leiden undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F9 · price: Open market sales reported on this line occurred at a weighted average price of $283.86 (range $283.35 to $284.30). Read SEC document |
| May 12, 2020 Filed May 14, 2020 20:19 UTC |
LEIDEN JEFFREY MDirector · Executive Chairman
|
SaleCommon Stock | 9,780 | $282.66 | $2,764,414.80 |
DisclosureSEC source: 0001209191-20-029186 · doc4.xml · nonDerivative · entry 10 LEIDEN JEFFREY M · CIK 0001242825 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 88,294 F1 · kind: Transaction made pursuant to Dr. Leiden's company approved trading plan under Rule 10b5-1. F3 · price: Dr. Leiden undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F8 · price: Open market sales reported on this line occurred at a weighted average price of $282.66 (range $282.33 to $283.28). Read SEC document |
| May 12, 2020 Filed May 14, 2020 20:19 UTC |
LEIDEN JEFFREY MDirector · Executive Chairman
|
SaleCommon Stock | 9,398 | $281.83 | $2,648,638.34 |
DisclosureSEC source: 0001209191-20-029186 · doc4.xml · nonDerivative · entry 9 LEIDEN JEFFREY M · CIK 0001242825 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 98,074 F1 · kind: Transaction made pursuant to Dr. Leiden's company approved trading plan under Rule 10b5-1. F3 · price: Dr. Leiden undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F7 · price: Open market sales reported on this line occurred at a weighted average price of $281.83 (range $281.29 to $282.24). Read SEC document |
| May 12, 2020 Filed May 14, 2020 20:19 UTC |
LEIDEN JEFFREY MDirector · Executive Chairman
|
SaleCommon Stock | 6,498 | $280.76 | $1,824,378.48 |
DisclosureSEC source: 0001209191-20-029186 · doc4.xml · nonDerivative · entry 8 LEIDEN JEFFREY M · CIK 0001242825 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 107,472 F1 · kind: Transaction made pursuant to Dr. Leiden's company approved trading plan under Rule 10b5-1. F3 · price: Dr. Leiden undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F6 · price: Open market sales reported on this line occurred at a weighted average price of $280.76 (range $280.17 to $281.13). Read SEC document |
| May 12, 2020 Filed May 14, 2020 20:19 UTC |
LEIDEN JEFFREY MDirector · Executive Chairman
|
SaleCommon Stock | 1,940 | $278.96 | $541,182.40 |
DisclosureSEC source: 0001209191-20-029186 · doc4.xml · nonDerivative · entry 7 LEIDEN JEFFREY M · CIK 0001242825 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 113,970 F1 · kind: Transaction made pursuant to Dr. Leiden's company approved trading plan under Rule 10b5-1. F3 · price: Dr. Leiden undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F5 · price: Open market sales reported on this line occurred at a weighted average price of $278.96 (range $278.71 to $279.10). Read SEC document |
| May 12, 2020 Filed May 14, 2020 20:19 UTC |
LEIDEN JEFFREY MDirector · Executive Chairman
|
SaleCommon Stock | 4,428 | $277.94 | $1,230,718.32 |
DisclosureSEC source: 0001209191-20-029186 · doc4.xml · nonDerivative · entry 6 LEIDEN JEFFREY M · CIK 0001242825 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 115,910 F1 · kind: Transaction made pursuant to Dr. Leiden's company approved trading plan under Rule 10b5-1. F3 · price: Dr. Leiden undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F4 · price: Open market sales reported on this line occurred at a weighted average price of $277.94 (range $277.63 to $278.41). Read SEC document |
| May 12, 2020 Filed May 14, 2020 20:19 UTC |
LEIDEN JEFFREY MDirector · Executive Chairman
|
SaleCommon Stock | 9,015 | $277.14 | $2,498,417.10 |
DisclosureSEC source: 0001209191-20-029186 · doc4.xml · nonDerivative · entry 5 LEIDEN JEFFREY M · CIK 0001242825 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 120,338 F1 · kind: Transaction made pursuant to Dr. Leiden's company approved trading plan under Rule 10b5-1. F2 · price: Open market sales reported on this line occurred at a weighted average price of $277.14 (range $276.63 to $277.61). F3 · price: Dr. Leiden undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. Read SEC document |
| May 12, 2020 Filed May 14, 2020 20:19 UTC |
LEIDEN JEFFREY MDirector · Executive Chairman
|
Exercise / conversionCommon Stock | 24,348 | $155.57 | $3,787,818.36 |
DisclosureSEC source: 0001209191-20-029186 · doc4.xml · nonDerivative · entry 4 LEIDEN JEFFREY M · CIK 0001242825 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 129,353 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 12, 2020 Filed May 14, 2020 20:19 UTC |
LEIDEN JEFFREY MDirector · Executive Chairman
|
Exercise / conversionCommon Stock | 4,470 | $91.05 | $406,993.50 |
DisclosureSEC source: 0001209191-20-029186 · doc4.xml · nonDerivative · entry 3 LEIDEN JEFFREY M · CIK 0001242825 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 105,005 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 12, 2020 Filed May 14, 2020 20:19 UTC |
LEIDEN JEFFREY MDirector · Executive Chairman
|
Exercise / conversionCommon Stock | 35,499 | $96.87 | $3,438,788.13 |
DisclosureSEC source: 0001209191-20-029186 · doc4.xml · nonDerivative · entry 2 LEIDEN JEFFREY M · CIK 0001242825 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,535 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 12, 2020 Filed May 14, 2020 20:19 UTC |
LEIDEN JEFFREY MDirector · Executive Chairman
|
Exercise / conversionCommon Stock | 24,215 | $187.53 | $4,541,038.95 |
DisclosureSEC source: 0001209191-20-029186 · doc4.xml · nonDerivative · entry 1 LEIDEN JEFFREY M · CIK 0001242825 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,036 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 11, 2020 Filed May 13, 2020 20:18 UTC |
Parini MichaelEVP, Chief Adm, Leg & BD Off
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 1,304 | $0.00 Strike: $187.53 | $0.00 |
DisclosureSEC source: 0001209191-20-028797 · doc4.xml · derivative · entry 3 Parini Michael · CIK 0001661567 · EVP, Chief Adm, Leg & BD Off 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,338 Underlying: Common Stock · 1,304 shares Expires 2029-02-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The option vests in 16 quarterly installments from 02/06/2019. Read SEC document |
| May 11, 2020 Filed May 13, 2020 20:18 UTC |
Parini MichaelEVP, Chief Adm, Leg & BD Off
|
SaleCommon Stock | 1,304 | $286.00 | $372,944.00 |
DisclosureSEC source: 0001209191-20-028797 · doc4.xml · nonDerivative · entry 2 Parini Michael · CIK 0001661567 · EVP, Chief Adm, Leg & BD Off 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,838 F1 · kind: Transaction made pursuant to Mr. Parini's company-approved trading plan under Rule 10b5-1. Read SEC document |
| May 11, 2020 Filed May 13, 2020 20:18 UTC |
Parini MichaelEVP, Chief Adm, Leg & BD Off
|
Exercise / conversionCommon Stock | 1,304 | $187.53 | $244,539.12 |
DisclosureSEC source: 0001209191-20-028797 · doc4.xml · nonDerivative · entry 1 Parini Michael · CIK 0001661567 · EVP, Chief Adm, Leg & BD Off 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,142 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 11, 2020 Filed May 13, 2020 20:20 UTC |
Sachdev AmitEVP, Chief Patient Officer
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 10,665 | $0.00 Strike: $131.89 | $0.00 |
DisclosureSEC source: 0001209191-20-028801 · doc4.xml · derivative · entry 14 Sachdev Amit · CIK 0001406338 · EVP, Chief Patient Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,665 shares Expires 2025-07-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F12 · derivative.exercise_date: Fully vested. Read SEC document |
| May 11, 2020 Filed May 13, 2020 20:20 UTC |
Sachdev AmitEVP, Chief Patient Officer
|
SaleCommon Stock | 100 | $286.72 | $28,672.00 |
DisclosureSEC source: 0001209191-20-028801 · doc4.xml · nonDerivative · entry 11 Sachdev Amit · CIK 0001406338 · EVP, Chief Patient Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,103 F1 · kind: Transaction made pursuant to Mr. Sachdev's company approved trading plan under Rule 10b5-1. Read SEC document |
| May 11, 2020 Filed May 13, 2020 20:20 UTC |
Sachdev AmitEVP, Chief Patient Officer
|
SaleCommon Stock | 1,367 | $285.94 | $390,879.98 |
DisclosureSEC source: 0001209191-20-028801 · doc4.xml · nonDerivative · entry 10 Sachdev Amit · CIK 0001406338 · EVP, Chief Patient Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,203 F1 · kind: Transaction made pursuant to Mr. Sachdev's company approved trading plan under Rule 10b5-1. F3 · price: Mr. Sachdev undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F11 · price: Open market sales reported on this line occurred at a weighted average price of $285.94 (range $285.63 to $286.59). Read SEC document |
| May 11, 2020 Filed May 13, 2020 20:20 UTC |
Sachdev AmitEVP, Chief Patient Officer
|
SaleCommon Stock | 2,314 | $285.15 | $659,837.10 |
DisclosureSEC source: 0001209191-20-028801 · doc4.xml · nonDerivative · entry 9 Sachdev Amit · CIK 0001406338 · EVP, Chief Patient Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,570 F1 · kind: Transaction made pursuant to Mr. Sachdev's company approved trading plan under Rule 10b5-1. F3 · price: Mr. Sachdev undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F10 · price: Open market sales reported on this line occurred at a weighted average price of $285.15 (range $284.57 to $285.55). Read SEC document |
| May 11, 2020 Filed May 13, 2020 20:20 UTC |
Sachdev AmitEVP, Chief Patient Officer
|
SaleCommon Stock | 1,100 | $283.98 | $312,378.00 |
DisclosureSEC source: 0001209191-20-028801 · doc4.xml · nonDerivative · entry 8 Sachdev Amit · CIK 0001406338 · EVP, Chief Patient Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,884 F1 · kind: Transaction made pursuant to Mr. Sachdev's company approved trading plan under Rule 10b5-1. F3 · price: Mr. Sachdev undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F9 · price: Open market sales reported on this line occurred at a weighted average price of $283.98 (range $283.57 to $284.44). Read SEC document |
| May 11, 2020 Filed May 13, 2020 20:20 UTC |
Sachdev AmitEVP, Chief Patient Officer
|
SaleCommon Stock | 913 | $282.89 | $258,278.57 |
DisclosureSEC source: 0001209191-20-028801 · doc4.xml · nonDerivative · entry 7 Sachdev Amit · CIK 0001406338 · EVP, Chief Patient Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,984 F1 · kind: Transaction made pursuant to Mr. Sachdev's company approved trading plan under Rule 10b5-1. F3 · price: Mr. Sachdev undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F8 · price: Open market sales reported on this line occurred at a weighted average price of $282.89 (range $282.44 to $283.24). Read SEC document |
| May 11, 2020 Filed May 13, 2020 20:20 UTC |
Sachdev AmitEVP, Chief Patient Officer
|
SaleCommon Stock | 1,398 | $281.74 | $393,872.52 |
DisclosureSEC source: 0001209191-20-028801 · doc4.xml · nonDerivative · entry 6 Sachdev Amit · CIK 0001406338 · EVP, Chief Patient Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,897 F1 · kind: Transaction made pursuant to Mr. Sachdev's company approved trading plan under Rule 10b5-1. F3 · price: Mr. Sachdev undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F7 · price: Open market sales reported on this line occurred at a weighted average price of $281.74 (range $281.33 to $282.29). Read SEC document |
| May 11, 2020 Filed May 13, 2020 20:20 UTC |
Sachdev AmitEVP, Chief Patient Officer
|
SaleCommon Stock | 1,817 | $280.77 | $510,159.09 |
DisclosureSEC source: 0001209191-20-028801 · doc4.xml · nonDerivative · entry 5 Sachdev Amit · CIK 0001406338 · EVP, Chief Patient Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,295 F1 · kind: Transaction made pursuant to Mr. Sachdev's company approved trading plan under Rule 10b5-1. F3 · price: Mr. Sachdev undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F6 · price: Open market sales reported on this line occurred at a weighted average price of $280.77 (range $280.33 to $281.26). Read SEC document |
| May 11, 2020 Filed May 13, 2020 20:20 UTC |
Sachdev AmitEVP, Chief Patient Officer
|
SaleCommon Stock | 655 | $279.67 | $183,183.85 |
DisclosureSEC source: 0001209191-20-028801 · doc4.xml · nonDerivative · entry 4 Sachdev Amit · CIK 0001406338 · EVP, Chief Patient Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,112 F1 · kind: Transaction made pursuant to Mr. Sachdev's company approved trading plan under Rule 10b5-1. F3 · price: Mr. Sachdev undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F5 · price: Open market sales reported on this line occurred at a weighted average price of $279.67 (range $279.21 to $280.05). Read SEC document |
| May 11, 2020 Filed May 13, 2020 20:20 UTC |
Sachdev AmitEVP, Chief Patient Officer
|
SaleCommon Stock | 201 | $277.38 | $55,753.38 |
DisclosureSEC source: 0001209191-20-028801 · doc4.xml · nonDerivative · entry 3 Sachdev Amit · CIK 0001406338 · EVP, Chief Patient Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,767 F1 · kind: Transaction made pursuant to Mr. Sachdev's company approved trading plan under Rule 10b5-1. F3 · price: Mr. Sachdev undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F4 · price: Open market sales reported on this line occurred at a weighted average price of $277.38 (range $277.26 to $277.50). Read SEC document |
| May 11, 2020 Filed May 13, 2020 20:20 UTC |
Sachdev AmitEVP, Chief Patient Officer
|
SaleCommon Stock | 800 | $276.25 | $221,000.00 |
DisclosureSEC source: 0001209191-20-028801 · doc4.xml · nonDerivative · entry 2 Sachdev Amit · CIK 0001406338 · EVP, Chief Patient Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,968 F1 · kind: Transaction made pursuant to Mr. Sachdev's company approved trading plan under Rule 10b5-1. F2 · price: Open market sales reported on this line occurred at a weighted average price of $276.25 (range $275.73 to $276.52). F3 · price: Mr. Sachdev undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. Read SEC document |
| May 11, 2020 Filed May 13, 2020 20:20 UTC |
Sachdev AmitEVP, Chief Patient Officer
|
Exercise / conversionCommon Stock | 10,665 | $131.89 | $1,406,606.85 |
DisclosureSEC source: 0001209191-20-028801 · doc4.xml · nonDerivative · entry 1 Sachdev Amit · CIK 0001406338 · EVP, Chief Patient Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,768 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 07, 2020 Filed May 8, 2020 20:20 UTC |
LEIDEN JEFFREY MDirector · Executive Chairman
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 24,349 | $0.00 Strike: $155.57 | $0.00 |
DisclosureSEC source: 0001209191-20-027890 · doc4.xml · derivative · entry 15 LEIDEN JEFFREY M · CIK 0001242825 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,348 Underlying: Common Stock · 24,349 shares Expires 2028-02-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F9 · derivative.exercise_date: Fully vested. Read SEC document |
| May 07, 2020 Filed May 8, 2020 20:20 UTC |
LEIDEN JEFFREY MDirector · Executive Chairman
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 4,470 | $0.00 Strike: $91.05 | $0.00 |
DisclosureSEC source: 0001209191-20-027890 · doc4.xml · derivative · entry 14 LEIDEN JEFFREY M · CIK 0001242825 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 98,336 Underlying: Common Stock · 4,470 shares Expires 2026-02-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F9 · derivative.exercise_date: Fully vested. Read SEC document |
| May 07, 2020 Filed May 8, 2020 20:20 UTC |
LEIDEN JEFFREY MDirector · Executive Chairman
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 35,499 | $0.00 Strike: $96.87 | $0.00 |
DisclosureSEC source: 0001209191-20-027890 · doc4.xml · derivative · entry 13 LEIDEN JEFFREY M · CIK 0001242825 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,499 Underlying: Common Stock · 35,499 shares Expires 2024-07-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F9 · derivative.exercise_date: Fully vested. Read SEC document |
| May 07, 2020 Filed May 8, 2020 20:20 UTC |
LEIDEN JEFFREY MDirector · Executive Chairman
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 24,216 | $0.00 Strike: $187.53 | $0.00 |
DisclosureSEC source: 0001209191-20-027890 · doc4.xml · derivative · entry 12 LEIDEN JEFFREY M · CIK 0001242825 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,215 Underlying: Common Stock · 24,216 shares Expires 2029-02-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F9 · derivative.exercise_date: Fully vested. Read SEC document |
| May 07, 2020 Filed May 8, 2020 20:20 UTC |
LEIDEN JEFFREY MDirector · Executive Chairman
|
SaleCommon Stock | 5,607 | $272.41 | $1,527,402.87 |
DisclosureSEC source: 0001209191-20-027890 · doc4.xml · nonDerivative · entry 10 LEIDEN JEFFREY M · CIK 0001242825 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,821 F1 · kind: Transaction made pursuant to Dr. Leiden's company approved trading plan under Rule 10b5-1. F3 · price: Dr. Leiden undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F8 · price: Open market sales reported on this line occurred at a weighted average price of $272.41 (range $272.17 to $272.77). Read SEC document |
| May 07, 2020 Filed May 8, 2020 20:20 UTC |
LEIDEN JEFFREY MDirector · Executive Chairman
|
SaleCommon Stock | 14,131 | $271.61 | $3,838,120.91 |
DisclosureSEC source: 0001209191-20-027890 · doc4.xml · nonDerivative · entry 9 LEIDEN JEFFREY M · CIK 0001242825 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,428 F1 · kind: Transaction made pursuant to Dr. Leiden's company approved trading plan under Rule 10b5-1. F3 · price: Dr. Leiden undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F7 · price: Open market sales reported on this line occurred at a weighted average price of $271.61 (range $271.17 to $272.15). Read SEC document |
| May 07, 2020 Filed May 8, 2020 20:20 UTC |
LEIDEN JEFFREY MDirector · Executive Chairman
|
SaleCommon Stock | 13,885 | $270.43 | $3,754,920.55 |
DisclosureSEC source: 0001209191-20-027890 · doc4.xml · nonDerivative · entry 8 LEIDEN JEFFREY M · CIK 0001242825 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,559 F1 · kind: Transaction made pursuant to Dr. Leiden's company approved trading plan under Rule 10b5-1. F3 · price: Dr. Leiden undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F6 · price: Open market sales reported on this line occurred at a weighted average price of $270.43 (range $270.02 to $271.00). Read SEC document |
| May 07, 2020 Filed May 8, 2020 20:20 UTC |
LEIDEN JEFFREY MDirector · Executive Chairman
|
SaleCommon Stock | 30,237 | $269.52 | $8,149,476.24 |
DisclosureSEC source: 0001209191-20-027890 · doc4.xml · nonDerivative · entry 7 LEIDEN JEFFREY M · CIK 0001242825 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 74,444 F1 · kind: Transaction made pursuant to Dr. Leiden's company approved trading plan under Rule 10b5-1. F3 · price: Dr. Leiden undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F5 · price: Open market sales reported on this line occurred at a weighted average price of $269.52 (range $269.02 to $270.01). Read SEC document |
| May 07, 2020 Filed May 8, 2020 20:20 UTC |
LEIDEN JEFFREY MDirector · Executive Chairman
|
SaleCommon Stock | 24,617 | $268.63 | $6,612,864.71 |
DisclosureSEC source: 0001209191-20-027890 · doc4.xml · nonDerivative · entry 6 LEIDEN JEFFREY M · CIK 0001242825 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 104,681 F1 · kind: Transaction made pursuant to Dr. Leiden's company approved trading plan under Rule 10b5-1. F3 · price: Dr. Leiden undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F4 · price: Open market sales reported on this line occurred at a weighted average price of $268.83 (range $268.02 to $269.01). Read SEC document |
| May 07, 2020 Filed May 8, 2020 20:20 UTC |
LEIDEN JEFFREY MDirector · Executive Chairman
|
SaleCommon Stock | 5,892 | $267.52 | $1,576,227.84 |
DisclosureSEC source: 0001209191-20-027890 · doc4.xml · nonDerivative · entry 5 LEIDEN JEFFREY M · CIK 0001242825 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 129,298 F1 · kind: Transaction made pursuant to Dr. Leiden's company approved trading plan under Rule 10b5-1. F2 · price: Open market sales reported on this line occurred at a weighted average price of $267.52 (range $266.97 to $267.94). F3 · price: Dr. Leiden undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. Read SEC document |
| May 07, 2020 Filed May 8, 2020 20:20 UTC |
LEIDEN JEFFREY MDirector · Executive Chairman
|
Exercise / conversionCommon Stock | 24,349 | $155.57 | $3,787,973.93 |
DisclosureSEC source: 0001209191-20-027890 · doc4.xml · nonDerivative · entry 4 LEIDEN JEFFREY M · CIK 0001242825 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 135,190 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.